Compare AbCellera Biologics Inc (ABCL) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Ecolab Inc. — how do they compare? AbCellera Biologics Inc trades at $9.74 (market cap $2.85B), while Ecolab Inc. trades at $285.03 (market cap $79.73B). The key difference: Ecolab Inc. is far larger — about 28× AbCellera Biologics Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ECL | |
|---|---|---|
Market Cap | $2.85B | $79.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.34 | $308.35 |
52-Week Low | $2.78 | $245.73 |
Enterprise Value | $2.45B | $88.51B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
ECL trades at $285.17, up 0.6% today, with a bullish technical signal and strong analyst support. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance. Revenue growth remains steady, with a net income margin of 12.57% and robust cash flow from operations of $2.95B in 2025. Recent news highlights dividend declarations and institutional buying interest.
Outlook is positive with a consensus price target of $327.90, implying 15% upside. Risks include elevated valuation multiples and potential margin pressure from input costs. The stock's momentum is supported by earnings beats and strategic acquisitions, but investors should monitor debt levels and competitive dynamics in the water and hygiene sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
